Literature DB >> 20652962

ACEi/ARB for systolic heart failure: closing the quality gap with a sustainable intervention at an academic medical center.

Qi Qian1, Dennis M Manning, Narith Ou, Mark J Klarich, Dorinda J Leutink, Ann R Loth, Francisco Lopez-Jimenez.   

Abstract

BACKGROUND: National guidelines recommend angiotensin converting enzyme inhibitor (ACEi) or angiotensinogen receptor blocker (ARB) therapy for patients with left ventricular systolic dysfunction (LVSD), including those with symptomatic heart failure (HF). However, guideline adherence has not been optimal. The goal of this quality improvement project is to devise and implement a sustainable care-delivery model in a 920-bed academic hospital center that would improve ACEi/ARB adherence before hospital discharge.
METHODS: The Model of intervention is: (1) a computer-based daily screening program; (2) inpatient pharmacist e-flag message; and (3) alerts for inpatient care teams. Its operating algorithm: If eligible adult HF/LVSD inpatients are not on ACEi or ARB nor documentation of contraindications, a flag alert is generated; deficiency is confirmed by a pharmacist and conveyed to the patient-care teams; if alert is acted on and care brought into adherence, the screening program would not re-flag the same patients the succeeding day; if not, the patients would be re-flagged daily until reaching adherence. We compared ACEi/ARB adherence before, during, and after the intervention.
RESULTS: Baseline performance (percentage of eligible HF/LVSD patients receiving ACEi/ARB) was 87.5%. After implementation of the Model the ACEi/ARB adherence rate at the time of hospital discharge rose to 96.7% (P < 0.002) and was sustained for 21 months without needing additional personnel.
CONCLUSIONS: A carefully designed, computer-based care-delivery model is highly efficient and sustainable for enhancing ACEi/ARB adherence. 2010 Society of Hospital Medicine.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20652962     DOI: 10.1002/jhm.803

Source DB:  PubMed          Journal:  J Hosp Med        ISSN: 1553-5592            Impact factor:   2.960


  6 in total

1.  The effect of captopril and losartan on the electrophysiology of myocardial cells of myocardial ischemia rats.

Authors:  Xiangmin Shi; Zhaoling Shan; Hongtao Yuan; Hongyang Guo; Yutang Wang
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  Interrupting providers with clinical decision support to improve care for heart failure.

Authors:  Saul Blecker; Jonathan S Austrian; Leora I Horwitz; Gilad Kuperman; Donna Shelley; Meg Ferrauiola; Stuart D Katz
Journal:  Int J Med Inform       Date:  2019-09-04       Impact factor: 4.046

3.  Effect of telmisartan and enalapril on ventricular remodeling and kidney prognosis of patients with coronary artery disease complicated with diabetic nephropathy.

Authors:  Yuyan Hou; Fucheng Zhang; Zhiqiang Liu; Shuhong Su; Xiao Wu; Zhifang Wang
Journal:  Exp Ther Med       Date:  2016-11-29       Impact factor: 2.447

Review 4.  Effectiveness of implementation interventions in improving physician adherence to guideline recommendations in heart failure: a systematic review.

Authors:  Deepti Shanbhag; Ian D Graham; Karen Harlos; R Brian Haynes; Itzhak Gabizon; Stuart J Connolly; Harriette Gillian Christine Van Spall
Journal:  BMJ Open       Date:  2018-03-06       Impact factor: 2.692

5.  Applying Clinical Decision Support Design Best Practices With the Practical Robust Implementation and Sustainability Model Versus Reliance on Commercially Available Clinical Decision Support Tools: Randomized Controlled Trial.

Authors:  Katy E Trinkley; Miranda E Kroehl; Michael G Kahn; Larry A Allen; Tellen D Bennett; Gary Hale; Heather Haugen; Simeon Heckman; David P Kao; Janet Kim; Daniel M Matlock; Daniel C Malone; Robert L Page Nd; Jessica Stine; Krithika Suresh; Lauren Wells; Chen-Tan Lin
Journal:  JMIR Med Inform       Date:  2021-03-22

Review 6.  Systematic review of clinical decision support interventions with potential for inpatient cost reduction.

Authors:  Christopher L Fillmore; Bruce E Bray; Kensaku Kawamoto
Journal:  BMC Med Inform Decis Mak       Date:  2013-12-17       Impact factor: 2.796

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.